Silk Road Medical (Silk Road Medical) Risk Assessment

View and export this data going back to 2019. Start your Free Trial

What is Silk Road Medical Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Silk Road Medical is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Silk Road Medical's Risk Assessment

For the Medical Devices subindustry, Silk Road Medical's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silk Road Medical's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Silk Road Medical's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Silk Road Medical's Risk Assessment falls into.

Silk Road Medical (NAS:SILK) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Silk Road Medical Risk Assessment Related Terms

Thank you for viewing the detailed overview of Silk Road Medical's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Silk Road Medical (Silk Road Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Silk Road Medical Inc (NAS:SILK) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

2OW:Germany

Address

1213 Innsbruck Drive, Sunnyvale, CA, USA, 94089

Website

https://www.silkroadmed.com

Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.

Executives

Chas Mckhann	director, officer: Chief Executive Officer	1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025
Marie L. Jones	officer: CAO and VP, Finance	1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Lucas W. Buchanan	officer: Chief Financial Officer	C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Kevin M Klemz	officer: EVP/Chief Legal Officer/Sec.	9600 54TH AVENUE NORTH, SUITE 100, PLYMOUTH MN 55442
Andrew S. Davis	officer: Chief Commercial Officer	C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Erica J. Rogers	director, officer: President and CEO	C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Elizabeth H Weatherman	director	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Richard Ruedy	officer: EVP Clin & Reg. Affairs and QA	C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Tony M. Chou	director	C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089
Tanisha Carino	director	C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON MA 02210
Kevin J. Ballinger	director	C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Rick D Anderson	director	3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746
Donald Zurbay	director	C/O ST. JUDE MEDICAL, INC., ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN 55117
Warburg Pincus Partners Gp Llc	10 percent owner	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
Warburg Pincus & Co.	10 percent owner	450 LEXINGTON AVENUE, NEW YORK, NY NY 100173147